It plans to expand its supply of Moderna vaccines in Aug/Sep

Inoculation will not be affected even if there is a supply disruption

It plans to expand its supply of Moderna vaccines in August and September.

 

Samsung Biologics' distribution in Korea is still pending.

 

A government delegation to the U.S.

 

announced the results after visiting Moderna The government received an apology from Moderna for the disruption in the domestic supply of COVID vaccines and announced that it will receive more domestic supplies this month and next month and move up the supply schedule early next month.

 

However, the government avoided giving a definite answer as there are many obstacles such as contracts between companies regarding supplying models or products that Samsung Biologics is consigned to Korea first.

 

At the COVID-19 Central Disaster and Safety Counters Headquarters, video conference held today (the 17th), the delegation consisting of Kang Do-tae, the second vice minister, and Ryu Geun-hyuk, the presidential secretary for social policy, reported last week's visit to the U.S.

 

Moderna headquarters, and the company's recent discussion on vaccine supply disruption and supply stabilization.

 

According to the MOHW and Central Disaster and Safety Counters Headquaters, during the visit, Moderna apologized for the government and people's difficulties caused by sudden supply disruptions, and explained that the manufacturing laboratory problems at cooperative manufacturers are now being resolved and gradually released in July.

 

The government asked the company to provide supplies that could not be supplied from August to early September, and to inform the schedule by this week, and Moderna said it would do its best to supply supplies and notify the government of its supply plan.

 

In particular, the government has not received a clear answer on how it can supply production volume of Samsung Biologics, which is consigned to produce Moderna vaccines, to South Korea.

 

In an answer to a regular briefing question, Vice Minister Kang Do-tae said, "It is desirable that domestic consignment production supplies are supplied to Korea in terms of securing safety in the supply of vaccines and streamlining the distribution process.

 

He added, "There is a need for continuous consultation on the contractual relationship between Samsung Biologics and Modena, and the interrelationship between companies and domestic administrative procedures" According to the government, there will be no significant disruption to the age-specific vaccination plan and achievement of the target.